Multiple Myeloma Coverage from Every Angle
Advertisement
Advertisement

Recent News

SOHO 2021: Does Prolonged Lenalidomide Maintenance Improve Survival After Transplant in Myeloma?
SOHO 2021: Update on BCMA-Directed CAR T-Cell Therapy for Resistant Myeloma
SOHO 2021: ICARIA-MM Update on Isatuximab-Based Therapy for Multiple Myeloma
SOHO 2021: Survival Update From MAIA Trial on Daratumumab-Based Therapy in Myeloma
DREAMM-2: Sustained Activity Reported With Belantamab Mafodotin-blmf in Resistant Myeloma
Bone-Directed Therapy in Myeloma: How Often Should Bisphosphonates Be Given?
COVID-19 and Novel Agents for Myeloma: From a Single Center in the Czech Republic
Relapse-Associated Genetic Alterations and Drug-Specific Resistance in Myeloma
FDA Brief: Orphan Drug Designation for Two Novel Multiple Myeloma Treatments
COVID-19 Vaccine Responses Among Patients With Multiple Myeloma
Initial Results From Cohort A of CARTITUDE-2: Ciltacabtagene Autoleucel for Progressive Myeloma
ICARIA-MM: Updated Results With Isatuximab-Based Therapy for Resistant Myeloma
BOSTON Trial: Survival Outcomes With Selinexor in Elderly Patients With Multiple Myeloma
Trends in Multiple Myeloma–Related Inpatient Mortality
Can an MRD-Adaptive Study Design Help to De-escalate Therapy for Multiple Myeloma?
Comparing Two Oral Doublet Regimens for Resistant Multiple Myeloma
FDA Issues Safety Alert for Use of Melphalan Flufenamide in Multiple Myeloma
Subcutaneous Use of BCMA-CD3 Bispecific Monoclonal Antibody in Myeloma
Adding Daratumumab to Combination Therapy for Newly Diagnosed Multiple Myeloma
First-in-Human Trial of Bispecific IgG4 Antibody for Multiple Myeloma
FDA Approves Daratumumab and Hyaluronidase-fihj Combination Therapy for Multiple Myeloma
ASCT With Carfilzomib-Based Regimens in Newly Diagnosed Multiple Myeloma
EHA2021: ANDROMEDA Trial Update Supports Daratumumab-Based Therapy for AL Amyloidosis
ASCO2021: CARTITUDE-1 Update on Ciltacabtagene Autoleucel for Resistant Myeloma
EHA2021: MRD Negativity as Myeloma Treatment Endpoint for Maintenance Therapy
ASCO 2021: Early Trial Update of Teclistamab in Resistant Multiple Myeloma
FDA Brief: Teclistamab Receives Breakthrough Therapy Designation for Resistant Myeloma
EHA2021: Targeting BCMA in Early-Phase Study in Resistant Myeloma
ASCO 2021: Durvalumab-Based Therapy for Ultra-High–Risk Newly Diagnosed Myeloma
ASCO 2021: KarMMa Update of BCMA-Directed CAR T-Cell Therapy for Refractory Myeloma
EHA2021: Iberdomide-Based Regimens for Relapsed or Refractory Multiple Myeloma
EHA2021: MAIA Trial Update on Daratumumab-Based Therapy for Newly Diagnosed Myeloma
ASCO 2021: Interim Analysis of CASSIOPEIA Trial of Daratumumab Maintenance in Myeloma
ASCO 2021: Ixazomib Maintenance After HCT in High-Risk Multiple Myeloma
Final Evidence Report From ICER on Three Therapies Targeting BCMA for Myeloma
BCMA CAR T-Cell Therapy Granted Priority Review for Multiple Myeloma
Ixazomib, Lenalidomide, and Dexamethasone in Myeloma: Routine Clinical Practice Versus Clinical Trials
Selinexor-Based Triplet in Myeloma: Impact of Age and Frailty in BOSTON Trial
Combination of Novel Antimyeloma Prototype and Cyclopamine Under Study
Does the First COVID-19 Vaccine Dose Offer Protection for Patients With Multiple Myeloma?
Peritransplant Orthostatic Hypotension and Multiple Myeloma
Frailty-Guided Treatment Strategy for Newly Diagnosed Patients With Myeloma
Risk Factors for Bloodstream Infections and Early Mortality in Multiple Myeloma
Whole-Genome Sequencing May Offer Insights to Multiple Myeloma Precursor Conditions
AACR 2021: Synergistic Selinexor-Based Combinations and Companion Biomarkers in Myeloma
Newly Diagnosed Myeloma: Novel Scenario for Carfilzomib-Linked Thrombotic Microangiopathy
AACR 2021: Role of ROBO1 Receptor in Growth of Multiple Myeloma
Weekly Carfilzomib-Based Regimen in Resistant Myeloma: Phase II Trial
Novel Oral PIM Kinase Inhibitor Under Study in Resistant Multiple Myeloma
Newly Diagnosed Myeloma: Novel Scenario for Carfilzomib-Linked Thrombotic Microangiopathy
AACR 2021: Is Novel IKZF1/3 Degrader Active Against Multiple Myeloma?
Isatuximab/Pomalidomide/Dexamethasone in Myeloma: Is Prescreening Patients for Biomarkers Warranted?
ICER Releases Evidence Report on BCMA Therapies for Multiple Myeloma
Expert European Panel Provides Clinical Practice Guidelines for Multiple Myeloma
Use of Generic Pomalidomide in India for Resistant Multiple Myeloma
Daratumumab-Based Therapy for Myeloma: Patient-Reported Outcomes From CASTOR Trial
FDA Approves Isatuximab-irfc Combination Therapy for Multiple Myeloma
FDA Approves First Cell-Based Gene Therapy for Multiple Myeloma


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.